Literature DB >> 27107937

Enhancement of CD4(+) T cell response and survival via coexpressed OX40/OX40L in Graves' disease.

Qin Wang1, Bi-Min Shi2, Fang Xie3, Zhao-Yang Fu1, Yong-Jing Chen1, Jing-Nan An1, Yu Ma1, Cui-Ping Liu4, Xue-Kun Zhang1, Xue-Guang Zhang5.   

Abstract

OX40/OX40L pathway plays a very important role in the antigen priming T cells and effector T cells. In the present study, we aimed to examine the involvement of OX40/OX40L pathway in the activation of autoreactive T cells in patients with Grave's disease (GD). We found that OX40 and OX40L were constitutively coexpressed on peripheral CD4(+) T cells from GD patients using flow cytometry analysis. The levels of OX40 and OX40L coexpression on CD4(+) T cells were shown to be correlated with TRAbs. Cell proliferation assay showed that blocking OX40/OX40L signal inhibited T cell proliferation and survival, which suggested that OX40/OX40L could enhance CD4(+) T cell proliferation and maintain their long-term survival in GD by self-enhancing loop of T cell activation independent of APCs. Confocal microscopy and coimmunoprecipitation analysis further revealed that OX40 and OX40L formed a functional complex, which may facilitate signal transduction from OX40L to OX40 and contribute to the pathogenesis of GD.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Coexpression; Graves' disease; OX40/OX40L; T cell activation

Mesh:

Substances:

Year:  2016        PMID: 27107937     DOI: 10.1016/j.mce.2016.04.008

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  4 in total

1.  OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer.

Authors:  Juan Deng; Sha Zhao; Xiaoshen Zhang; Keyi Jia; Hao Wang; Caicun Zhou; Yayi He
Journal:  Onco Targets Ther       Date:  2019-09-06       Impact factor: 4.147

2.  The association between serum adenosine deaminase levels and Graves' disease.

Authors:  Chun-Feng Lu; Wang-Shu Liu; Xiao-Qin Ge; Feng Xu; Jian-Bin Su; Xue-Qin Wang; Yan Wang
Journal:  Endocr Connect       Date:  2021-09-28       Impact factor: 3.335

3.  Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis.

Authors:  Xiaoling Zhou; Xiaoyuan Wang; Yanzheng Gu; Lan Chen; Yueping Shen; Jingluan Tian; Chen Shujun; Mingyuan Wang; Xiaoyu Duan; Hanqing Gao; Xiaopei Ji; Qi Fang; Xueguang Zhang; Qun Xue
Journal:  J Immunol Res       Date:  2022-02-28       Impact factor: 4.818

Review 4.  Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity.

Authors:  Yu Fu; Qing Lin; Zhirong Zhang; Ling Zhang
Journal:  Acta Pharm Sin B       Date:  2019-09-03       Impact factor: 11.413

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.